Cencora Secures $4.5B Term Loans & Boosts Revolving Credit for OneOncology Acquisition

summarizeSummary

Cencora, Inc. secured $4.5 billion in new term loan facilities and increased its revolving credit facility by $1.0 billion to $5.5 billion, funding a previously announced acquisition and replacing bridge financing.

check_boxKey Events

• New Term Loan Facilities Secured

  Cencora entered into a multi-year term loan facility of $1.5 billion (Tranche One: $500M, 2-year maturity; Tranche Two: $1.0B, 3-year maturity) and a 364-day term credit facility of $3.0 billion. These facilities total $4.5 billion and will be used to fund a portion of the previously announced acquisition of OneOncology and repay existing debt of OneOncology.

• Revolving Credit Facility Increased

  The company amended its existing revolving credit facility, increasing the aggregate commitments by $1.0 billion to a total of $5.5 billion.

• Bridge Financing Replaced

  The $4.5 billion in previously obtained bridge financing commitments for the acquisition have been automatically reduced to zero, replaced by the new term loan facilities.

• Acquisition Funding

  The proceeds from the new term loans are specifically earmarked to pay a portion of the consideration for the OneOncology acquisition and to refinance existing debt of the acquired entity.

auto_awesomeAnalysis

Cencora has successfully secured substantial financing to support its strategic acquisition of OneOncology. The new $4.5 billion in term loan facilities, coupled with a $1.0 billion increase in its revolving credit facility, significantly bolsters the company's liquidity and financial flexibility. The replacement of bridge financing with these definitive agreements is a positive development, reducing uncertainty around the acquisition's funding structure. This indicates strong lender confidence in Cencora's financial health and strategic direction, despite the increase in overall indebtedness.